Evento

Involvement of the glycan-binding protein Galectin-1 in hepatocellular carcinoma cell drug resistance

Carabias, PabloIcon ; Bacigalupo, Maria LorenaIcon ; Rubin, Ayelen; Saffioti, Nicolas AndresIcon ; Elola, Maria TeresaIcon ; Lanari, Claudia; Rossi, Juan Pablo FranciscoIcon ; Wolfenstein, Carlota; Rojas, Paola AndreaIcon ; Rabinovich, Gabriel AdriánIcon ; Espelt, Maria VictoriaIcon ; Troncoso, María FernandaIcon
Tipo del evento: Congreso
Nombre del evento: Liver Cancer Summit 2020
Fecha del evento: 06/02/2020
Institución Organizadora: Asociación Europea para el Estudio del Hígado;
Título del Libro: Liver Cancer Summit
Editorial: Asociación Europea para el Estudio del Hígado
Idioma: Inglés
Clasificación temática:

Resumen

Hepatocellular carcinoma (HCC) is characterized by a high resistance to chemotherapy. P-glycoprotein (Pgp) is an ATP-dependent drug efflux pump and its overexpression in HCC is associated with a decrease in intracellular drug concentration, leading to chemotherapeutic tolerance. Galectin-1 (Gal1), a β-galactoside-binding protein, is overexpressed in HCC and it is related to tumor aggressiveness. Recent studies have shown that Gal1 may have a role in HCC chemoresistance. Our aim was to investigate the molecular basis of Gal1-mediated chemoresistance in HCC cells.
Palabras clave: GALECTIN1 , HEPATOCELLULAR CARCINOMA , DRUG RESISTANCE , DOXORRUBICINE
 
Archivos asociados
Thumbnail
 
Tamaño: 20.46Mb
Formato: PDF
.
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)
Identificadores
URI: http://hdl.handle.net/11336/218261
URL: https://easl.eu/livercancersummit2020/abstracts/
Colecciones
Eventos(IBYME)
Eventos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Involvement of the glycan-binding protein Galectin-1 in hepatocellular carcinoma cell drug resistance; Liver Cancer Summit 2020; Praga; República Checa; 2020; 193-193
Compartir